-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the journal Cancer published the results of a retrospective propensity-matched analysis from Fudan University Cancer Hospital , mainly evaluating the use of short-course (2-3 years) adjuvant in patients with ER-positive low-expression (IHC 1%-10%) breast cancer.
Recently, the journal Cancer published the results of a retrospective propensity-matched analysis from Fudan University Cancer Hospital .
From 2012 to 2017, 22,768 patients were pathologically confirmed early breast cancer, of which 1013 (4.
From 2012 to 2017, 22,768 patients were pathologically confirmed early breast cancer, of which 1013 (4.
At a median follow-up of 65 months (interquartile range 44-72 months), the estimated 5-year DFS rate for the entire study cohort was 85.
At a median follow-up of 65 months (interquartile range 44-72 months), the estimated 5-year DFS rate for the entire study cohort was 85.
The results showed that in univariate analysis (HR, 0.
The results showed that in univariate analysis (HR, 0.
In propensity-matched post-analysis, univariate analysis showed no significant improvement in DFS in patients who received 5 years of endocrine therapy compared with those who received 2 to 3 years of endocrine therapy (HR, 0.
In propensity-matched post-analysis, univariate analysis showed no significant improvement in DFS in patients who received 5 years of endocrine therapy compared with those who received 2 to 3 years of endocrine therapy (HR, 0.
There were no statistically significant differences in DFS in subgroup analyses of patients with endocrine therapy for 2-3 years and 5 years before and after propensity-matched analysis
We also examined changes in ER status in recurrent lesions in ER-positive, low-expressing breast cancers .
We also examined changes in ER status in recurrent lesions in ER-positive, low-expressing breast cancers .
In conclusion, the study shows that for patients with ER-positive low expression (IHC 1%-10%) breast cancer, short-course (2-3 years) adjuvant endocrine therapy is the treatment option of choice
Original source:
Cai YW, Shao ZM, Yu KD.
leave a message here
